Anzeige
Mehr »
Montag, 15.09.2025 - Börsentäglich über 12.000 News
Diese Aktie meldet Mega-Deal: Nokia & Ericsson an Bord!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12A5F | ISIN: CA31447P1009 | Ticker-Symbol: RV41
Tradegate
15.09.25 | 09:31
7,650 Euro
+2,00 % +0,150
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
FENNEC PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
FENNEC PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,3007,60012:01
7,3007,60011:37

Aktuelle News zur FENNEC PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.08.Fennec Pharmaceuticals Inc Q2 Loss Decreases, But Misses Estimates2
14.08.Fennec Pharmaceuticals GAAP EPS of -$0.11 misses by $0.08, revenue of $9.65M beats by $0.09M1
14.08.Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update399~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community...
► Artikel lesen
13.08.Fennec Pharmaceuticals Earnings Preview1
11.08.Fennec Pharmaceuticals Inc: Fennec Pharmaceuticals to release Q2 results Aug. 142
FENNEC PHARMACEUTICALS Aktie jetzt für 0€ handeln
11.08.Stocks in Play: Fennec Pharmaceuticals Inc.1
11.08.Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 20251
04.06.Fennec Pharmaceuticals Inc: Fennec shareholders approve all matters at AGSM1
03.06.Fennec Pharmaceuticals elects board members, shareholders approve proposals1
03.06.Fennec Pharmaceuticals Inc.: Fennec Announces Results of Annual Meeting235RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the "Company") (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy...
► Artikel lesen
03.06.FENNEC PHARMACEUTICALS INC. - 8-K, Current Report1
13.05.Fennec Pharmaceuticals GAAP EPS of -$0.04 beats by $0.05, revenue of $8.75M beats by $0.57M1
13.05.Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update168~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company's Refined, Targeted Sales Strategy and Enhanced Patient Support Services...
► Artikel lesen
09.05.Fennec Pharmaceuticals Inc: Fennec to release Q1 results, host call May 132
08.05.Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 202510
26.03.FENNEC PHARMACEUTICALS INC. - 10-K, Annual Report4
10.03.Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update187~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6...
► Artikel lesen
07.02.Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI In Germany258~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to ~ Norgine Pharmaceuticals'...
► Artikel lesen
20.12.24Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces Pedmarqsi Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales194~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and...
► Artikel lesen
07.11.24Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update160~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1